Non-Drug Myostatin Strategies: What Studies Show

What this section covers

Myostatin is a protein that muscle makes to limit its own growth. Our myostatin inhibitors hub covers the drugs and research chemicals that block it. This page covers the other route: things people do without a drug that are said to lower myostatin signaling. Two child pages go into more detail. The page on training and myostatin covers exercise programming, and the page on diet and supplements for myostatin covers food and supplement choices. This overview sets out what the human evidence shows for each approach and how it compares with the antibody drugs.

One caution applies to almost every study below. They measure a marker, either myostatin mRNA in a muscle biopsy or myostatin protein in blood, rather than the muscle itself. A lower marker isn't the same as more muscle, and the two don't always move together. Blood tests add another problem. A Danish research group found that one myostatin antibody also picked up a protein band in muscle from mice that have no myostatin gene, so some assays may be measuring more than myostatin.

Resistance training and muscle myostatin

Resistance training has the strongest human data of anything on this page. After 9 weeks of heavy single-leg knee extensions, 15 men and women in a 2003 study had 37% less myostatin mRNA in the trained thigh. The drop didn't correlate with how much strength or muscle volume each person gained.

Single workouts show a short-term effect. In a 2007 Ball State University study, six experienced lifters had thigh biopsies taken repeatedly for a day after one resistance session. Myostatin mRNA fell about sixfold and stayed low from 1 to 24 hours afterward.

Pooled data point the same way for blood levels. A 2023 meta-analysis of 26 randomized studies with 768 adults (aged roughly 18 to 82) found that resistance training lowered circulating myostatin and raised follistatin compared with controls who didn't exercise, at every age studied. A 2026 meta-analysis limited to frail or sarcopenic older adults found a much smaller reduction and rated the certainty of the evidence as very low.

How large and how lasting the drop is

The training effect is real but modest, and not every study finds it. A 2004 study of 22 untrained men found that 12 weeks of heavy lower-body training raised both myostatin mRNA and serum myostatin, even though the men gained strength and fat-free mass.

A 2007 Finnish study in older men helps make sense of the mixed results. Over 21 weeks of training, resting myostatin mRNA went up. Yet a single workout lowered it, and that acute drop appeared only once the men were trained. Men whose myostatin fell most after a workout gained the most muscle overall. So training may lower myostatin mainly in the hours after each session, while resting levels vary from study to study.

The effect also reverses when training stops. In another Danish study, young men trained for 90 days and then stopped. Myostatin mRNA rose during detraining, and the men lost almost half of their newly gained type II muscle fiber area within 10 days. Whatever training does to myostatin, it seems to last only as long as the training does.

Supplements marketed as myostatin blockers

Several supplements are sold with myostatin claims. The human evidence for each is thin, and none has been shown to add muscle by lowering myostatin.

Creatine. In a 2010 double-blind trial from Iran, 27 healthy young men were randomized. Two groups trained (one with creatine, one with a placebo) while a third group didn't. Eight weeks of training lowered serum myostatin, and creatine plus training lowered it further. That's one small trial using a blood assay, and we didn't find a replication in our search.

Epicatechin. This cocoa flavanol's human data started with a 2014 proof-of-concept study: six adults took it for 7 days with no placebo group, and the ratio of plasma follistatin to myostatin went up along with grip strength. A 2019 randomized trial in 62 older men with sarcopenia then tested it for 8 weeks with and without resistance training. Myostatin fell significantly only in the two groups that trained. Epicatechin on its own didn't lower it, though the training-plus-epicatechin group had the largest rise in follistatin.

Vitamin D. A 2015 Danish trial gave 40 healthy untrained men vitamin D plus calcium or calcium alone for 16 weeks, with resistance training in the last 12. Young men taking vitamin D had lower myostatin mRNA than the placebo group. Neither age group gained more muscle size or strength from the vitamin D.

Fortetropin. This ingredient comes from fertilized egg yolk and is marketed as a myostatin reducer. In a 2023 McMaster University trial, 24 young men had one leg immobilized for two weeks. Plasma myostatin rose in the placebo group but not in the Fortetropin group, yet both groups lost the same amount of muscle and strength. The senior author disclosed research funding from Myos, the company behind the ingredient. A 2016 trial in 37 resistance-trained college men reported about 1.7 kg of lean mass gained over 12 weeks on Fortetropin versus 0.6 kg on placebo, with no difference in strength. Its abstract doesn't report myostatin levels in the human participants.

How this compares with myostatin drugs

The drug route works on a different scale. As of October 2026, the FDA has approved one myostatin-targeted drug: apitegromab (Isembyld), approved in September 2026 for spinal muscular atrophy (SMA) in patients aged 2 and older who already take an SMN2-targeted treatment. In its 52-week trial in children aged 2 to 12, 34.2% of treated patients had a clinically meaningful motor-function improvement, versus 13.5% on placebo. The label warns of an increased risk of fractures.

Two antibodies have also been tested during GLP-1 weight loss. In the BELIEVE Phase 2 trial (507 adults with obesity, Nature Medicine, 2026), people on semaglutide alone lost 4.7% to 6.9% of their lean mass at 48 weeks. Adding bimagrumab cut that loss to 0.8% to 2.3%, and bimagrumab alone slightly increased lean mass. In the COURAGE Phase 2 trial, presented at EASD in October 2026, the higher of two low doses of trevogrumab held 52-week lean-mass loss to 4.2%, versus 7.3% on semaglutide alone. Two participants died in a higher-dose arm that paired trevogrumab with garetosmab, a second antibody. Regeneron dropped that combination. Semaglutide in these trials is a prescription medicine; research-use-only versions sold online aren't equivalent.

The gap with training is mostly about what was measured. The drug trials enrolled hundreds of people and measured lean mass directly by DXA scan. The training and supplement studies mostly measured a marker in a few dozen people. We found no trial that has compared resistance training with a myostatin drug head-to-head, or tested whether training adds to a drug's effect. None of the trial drugs is the same as the follistatin or "ACE-031" vials sold online, which have no human data (see our follistatin page). For how the drugs stack up against anabolic steroids, see our comparison of myostatin inhibitors with anabolics.

What we still don't know

• How much of the muscle gained from training is due to lower myostatin. The 2003 study found no link between the two, while the 2007 Finnish study found a strong one.
• Whether any supplement lowers myostatin enough to matter. Each has one or two small trials, often from a single lab, and Fortetropin's human data are partly industry-funded.
• Whether resistance training during GLP-1 treatment preserves lean mass as well as the antibodies did in BELIEVE and COURAGE. As of October 2026, we found no trial that tested this directly against a myostatin drug.